Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 11Phase 1 7Phase 1/2 5Phase NA 4Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Head and Neck Neoplasms 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Mesothelioma 4Breast Neoplasms 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Urinary Bladder Neoplasms 2Osteosarcoma 2Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Bile Duct Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Testicular Neoplasms 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Cisplatin × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡